September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
13 citations
,
May 2007 in “Journal of Endocrinology” Synthetic 19-norprogestins promote bone cell growth and function through their non-phenolic metabolites.
75 citations
,
June 2019 in “International Journal of Molecular Sciences” Costunolide may have multiple health benefits, including promoting hair growth and protecting against cancer and diabetes, but more research is needed.
3 citations
,
April 2020 in “PubMed” Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.
COCs can improve acne but may cause skin issues like cholasma; high estrogen is advised for hair loss concerns.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
62 citations
,
December 1995 in “The Journal of Clinical Endocrinology & Metabolism” Combining a GnRH agonist with a low-dose oral contraceptive is more effective and safer for treating hirsutism than using either alone.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
January 2022 in “Pharmaceutical Sciences Asia” Liposomes with butterfly pea extract and clove oil are stable and effective according to users.
January 2026 in “Journal of Education Health and Sport” Letrozole with lifestyle changes improves fertility in women with PCOS.
28 citations
,
July 2022 in “Endocrine” Low prolactin in young women may increase heart and metabolism risks.
49 citations
,
June 1998 in “Journal of Endocrinological Investigation” Cyproterone acetate plus ethinyl estradiol is generally more effective in treating hirsutism, but consider side effects and patient characteristics.
November 2023 in “International Journal of Pharmaceutics” The new delivery system improves treatment for hair loss by enhancing drug absorption and effectiveness.
1 citations
,
May 2022 in “Frontiers in Pharmacology” Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
June 2023 in “Sri Lanka Journal of Menopause”
September 2025 in “Journal of the American Academy of Dermatology” Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.
33 citations
,
April 2015 in “Cochrane library” Some medicines can reduce excessive hair growth in women, but more research is needed to compare treatments and consider side effects.
Depo-Provera effectively prevents pregnancy but has many side effects and safety concerns, leading to its ban in the U.S.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
58 citations
,
January 2015 in “Journal of the American Academy of Dermatology” Pioglitazone may help treat lichen planopilaris, but more research is needed.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
11 citations
,
May 2022 in “World Journal of Biological Chemistry” Progesterone may help trans women with breast development and health, but more research is needed.
7 citations
,
May 2022 in “Indonesian Journal of Science and Technology” Compounds from Etlingera alba may help treat Triple Negative Breast Cancer.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
13 citations
,
June 2018 in “Journal of Womens Health” Combination therapy with oral contraceptives and spironolactone improves hair growth, menstrual issues, and acne in women with PCOS.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
January 2000 in “Expert Opinion on Therapeutic Patents” The document highlights various patents for new compounds with potential treatments for multiple diseases, including cancer, hormonal disorders, and diabetes.